New research suggests that individuals who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional diet and exercise regimens.
Published data in a major health publication shows that while overweight individuals often shed substantial amounts of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these drugs need to be cognizant of the potential of rapid weight regain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of recovery means a return to starting mass within about 18 months.
Comparing Treatments
The study, which reviewed dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Researchers emphasize that people who lose weight through dieting typically see a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the jabs explains the heightened rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of weight regain, the therapy might need to be ongoing.
This view is supported by pharmaceutical companies, who note that the findings "highlight the long-term character of obesity," similar to managing diseases like high blood pressure.
User Testimonies
Users who have come off the jabs explain a intense resurgence of cravings.
"It was like something flipping and I was suddenly starving," described one woman.
This challenge is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Use
Recent estimates show that millions of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is greater among females than males.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and maintained weight loss likely depends on combined behavioural management.
